Gold tier: mechanically validated evidence, with its primary source.
66 evidence items · page 3 / 3
5.9 odds_ratioIndividuals living in conflict zones in Nigeria were nearly six times as likely to test positive for hepatitis C (adjusted odds ratio = 5.90).
Nigeriahépatite Cobserved 2018published 2021Annals of global healthPubMeddocument of 12 observations
1.1 %The prevalence of HIV-hepatitis B-hepatitis C triple infection among people living with HIV/AIDS in a rural Northern Nigerian community was 1.1%.
Nigeriahépatite B · hépatite C · VIH/sidapublished 2020The Pan African medical journalPubMeddocument of 4 observations
120,522 patientsAs of December 2019, 120,522 patients initiated hepatitis C virus treatment.
Nigeriahépatite Cobserved December 2019published 2020BMJ global healthPubMeddocument of 6 observations
13.3 %The overall prevalence of HCV infection among diabetic patients assayed was 13.3%.
Nigeriahépatite Cpublished 2020BMC infectious diseasesPubMeddocument of 7 observations
1.8 %HCV was detected in 1.8% of 400 blood donors at the Federal Medical Center in Azare.
Nigeriahépatite Cpublished 2025BMC infectious diseasesPubMeddocument of 5 observations
8.9 %Among diabetic subjects with a history of sharing sharp objects, HCV seropositivity was 8.9%.
Nigeriahépatite Cpublished 2020BMC infectious diseasesPubMeddocument of 7 observations
0.8 %Prevalence of Anti-HCV among liver diseases patients in Osun State was 0.8%.
Nigeriahépatite Cpublished 2021Journal of immunoassay & immunochemistryPubMeddocument of 4 observations
29.2 %Among HIV-infected patients in Port Harcourt, the prevalence of HCV infection was 29.2% in the 31–35 age range.
Nigeriahépatite C · VIH/sidapublished 2021African health sciencesPubMeddocument of 4 observations
87 %Hepatitis C screening was performed in 27 out of 31 hospitals (87%).
Nigeriahépatite Cobserved 2014published 2016International healtheurope_pmcdocument of 11 observations
0.4 %Among 265 livestock handlers in Ibadan, Nigeria, 1 (0.4%) was coinfected with HBV and HCV.
Nigeriahépatite B · hépatite Cobserved October 2016 to April 2017published 2024African health sciencesPubMeddocument of 5 observations
0.64 %Among HIV-positive patients aged 31–40 years in the study, the prevalence of HIV/HBV/HCV triple infection was 0.64%.
Nigeriahépatite B · hépatite C · VIH/sidaobserved 2019published 2020Journal of immunoassay & immunochemistryPubMeddocument of 9 observations
14.9 %Among diabetic subjects with tertiary education, HCV seropositivity was 14.9%.
Nigeriahépatite Cpublished 2020BMC infectious diseasesPubMeddocument of 7 observations
80 US$Commodity costs for hepatitis C virus treatment fell to as low as US$80 per-cure commodity package, including WHO-prequalified generic drugs (sofosbuvir + daclatasvir).
Nigeriahépatite Cpublished 2020BMJ global healthPubMeddocument of 6 observations
0.14 %Among 2775 pregnant women in Nigeria, the seroprevalence of HIV-HCV dual infection was 0.14%.
Nigeriahépatite C · VIH/sidapublished 2025Antiviral therapyPubMeddocument of 7 observations
11.3 %Among male diabetic subjects, HCV seropositivity was 11.3%.
Nigeriahépatite Cpublished 2020BMC infectious diseasesPubMeddocument of 7 observations
81 individualsAmong those tested for hepatitis C in the medical outreach in Durum community, Bauchi State, Nigeria, 81 (41%) had positive results.
Nigeriahépatite Cobserved 2023published 2023West African journal of medicinePubMeddocument of 11 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.